Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML

By News Health
1 month Ago

(MedPage Today) — HOUSTON — Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.
A pooled analysis of data from…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117333

Author :

Publish date : 2025-09-05 18:48:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

How Many Young Adults Used Cannabis or Alcohol to Help Sleep?

'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC

AI and Healthcare; New Drug for Lupus

First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer

Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer

Add-On Multicancer Early Detection Test Promising Across Various Cancer Types